Next-generation smallpox vaccine being stockpiled
13 July 2010
The Associated Press
A Danish company has delivered the first 1 million doses of a
next-generation smallpox vaccine to the U.S. national stockpile, a
vaccine reserved for people with weakened immune systems.
The federal government has ordered 20 million doses of Bavarian
Nordic's Imvamune, a vaccine developed in part with U.S. research
money as part of the nation's preparations in case of a
bioterrorist attack.
The government has long stockpiled smallpox vaccine against such
a possibility. But the conventional vaccine, made with a live virus
that's a relative of smallpox, isn't safe for people with weakened
immune systems. Imvamune is made of a different strain of the
virus, targeted for the immune-compromised because it cannot
multiply in human cells.
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
